1.3.1.1 Professional Information for medicines for human use

SCHEDULING STATUS

S4

1 NAME OF THE MEDICINE

VIDAZA™ (100 mg, powder for suspension for injection)

2 QUALITIVE AND QUANTITIVE COMPOSITION

Each vial contains 100 mg azacitidine.

The reconstituted suspension contains 25 mg/ml azacitidine.

Contains sugar: Mannitol

For full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

White lyophilised powder.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

- VIDAZA is indicated for treatment of adult patients with Myelodysplastic syndromes (MDS) including the following subtypes of the French–American–British classification:
- Refractory anaemia (RA) according to the French-American-British classification (FAB) system, plus neutropenia or thrombocytopenia or requiring transfusions;

- Refractory anaemia with ringed sideroblasts (RARS) according to the FAB system, plus neutropenia or thrombocytopenia or requiring transfusions;
- Refractory anaemia with excess blasts (RAEB) according to the FAB system;
- Refractory anaemia with excess blasts in transformation (RAEB-T) according to the FAB system (or acute myeloid leukaemia with 20-30 % bone marrow blasts and multilineage dysplasia according to World Health Organisation (WHO) classification);
- VIDAZA is also indicated for treating adult patients with chronic myelomonocytic leukemia (CMML) according to the FAB system.
- Acute myeloid leukemia (AML) with > 30 % bone marrow blasts according to the WHO classification, in patients who are not eligible for hematopoietic stem cell transplantation (HSCT).

4.2 Posology and method of administration

Posology

VIDAZA treatment should be initiated and monitored under the supervision of a medical practitioner experienced in the use of chemotherapeutic medicines. Patients should be premedicated with anti-emetics for nausea and vomiting.

The recommended starting dose for the first treatment cycle, for all patients regardless of baseline haematology laboratory values, is 75 mg/m^2 of body surface area, daily for 7 days, followed by a rest period of 21 days (28-day treatment cycle). It is recommended that patients be treated for a minimum of 6 cycles. Treatment should be continued as long as the patient continues to benefit or until disease progression.

Patients should be monitored for haematological response/toxicity and renal toxicities (see section 4.8); a delay in starting the next cycle or a dose reduction as described below may be necessary.

Dosage Adjustment due to haematological toxicity:

Patients with baseline blood counts (i.e. White Blood Cells (WBC) > 3,0 x 10^9/l and absolute neutrophil count (ANC) > 1,5 x10^9/l, and platelets > 75,0 x 10^9/l).

If haematological toxicity is observed following VIDAZA treatment, the next cycle of VIDAZA therapy should be delayed until the platelet count and the ANC have recovered. If recovery is achieved within 14 days, no dose adjustment is necessary. However, if recovery has not been achieved within 14 days, the dose should be reduced according to the following table. Following dose modifications, the cycle duration should return to 28 days.

Nadir counts		% Dose in the next cycle, if recovery* is not achieved within 14 days
ANC (x10^9/ L)	Platelets (x10^9/ L)	
≤ 1,0	≤ 50,0	50 %
> 1,0	> 50,0	100 %

*Recovery= counts≥ Nadir count + (0,5 x [baseline count- Nadir count])

Patients baseline blood counts (i.e. WBC < 3,0 x 10^9/l or ANC < 1,5 x 10^9/l or platelets < 75,0 x10^9/l):

Following VIDAZA treatment, if the decrease in WBC or ANC or platelets from baseline is less than 50 %, or greater than 50 % but with an improvement in any cell line differentiation, the next cycle should not be delayed and no dose adjustment be made.

If the decrease in WBC or ANC or platelets is greater than 50 % from that prior to treatment, with no improvement in cell line differentiation, the next cycle of VIDAZA therapy should be delayed until the platelet count and the ANC have recovered.

If recovery is achieved within 14 days, no dose adjustment is necessary. However, if recovery has not been achieved within 14 days, bone marrow cellularity should be determined. If the bone marrow cellularity is > 50 %, no dose adjustments should be made.

If bone marrow cellularity is ≤ 50 %, treatment should be delayed and the dose reduced according to the following table:

Bone marrow cellularity	% Dose in the next cycle, if recovery is not achieved within 14 days	
	Recovery * ≤ 21 days	Recovery* > 21 days
15-50%	100%	50%
< 15%	100%	33%

*Recovery= counts≥ Nadir count + (0.5 x [baseline count- Nadir count])

Following dose modifications, the cycle duration should return to 28 days.

Special Populations

Patients with Renal Impairment:

VIDAZA can be administered to patients with renal impairment without initial dose adjustment. If unexplained reductions in serum bicarbonate levels to less than 20 mmol/l occur, the dose should be reduced by 50 % on the next cycle. If unexplained elevations in serum creatinine or blood urea occur, the next cycle should be delayed until values return to normal or baseline and the dose should be reduced by 50 % on the next treatment cycle (see section 4.4).

Patients with Hepatic Impairment:

No formal studies have been conducted in patients with hepatic impairment (see section 4.4).

VIDAZA is contraindicated in patients with malignant hepatic tumours (see sections 4.3 and 4.4).

Elderly:

No specific dose adjustments are recommended for the elderly. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function.

Paediatric population

VIDAZA is not recommended for use in children below 18 years of age, due to insufficient data on safety and efficacy.

Laboratory Tests

Liver function tests and serum creatinine should be determined prior to initiation of therapy. Complete blood counts should be performed prior to initiation of therapy and as needed to monitor response and toxicity, but at a minimum, prior to each treatment cycle

Method of Administration

Subcutaneous injection:

- VIDAZA should be injected subcutaneously into the upper arm, thigh or abdomen.
- Injection sites should be rotated.
- New injections should be given at least 2,5 cm from the previous site and never into areas where the site is tender, bruised, red, or hardened.

Recommendations for safe handling

- VIDAZA is a cytotoxic medicine and, as with other potentially toxic compounds, caution should be exercised when handling and preparing VIDAZA suspensions.
- Procedures for proper handling and disposal of anticancer medicines should be applied.
- If reconstituted VIDAZA comes into contact with the skin, immediately and thoroughly wash with soap and water.

- If it comes into contact with mucous membranes, flush thoroughly with water.

Preparation for the subcutaneous administration:

- VIDAZA must be reconstituted to form a uniform suspension prior to administration.
- Add 4 ml of sterilised water for injections.
- Vigorously shake the vial until a uniform cloudy suspension is achieved.
- Do not filter the suspension after reconstitution as this could remove the active substance.
- The suspension contains azacitidine 25 mg/ml.
- To provide a homogeneous suspension, the contents of the syringe must be re-suspended immediately prior to administration.
- To re-suspend, vigorously roll the syringe between the palms until a uniform cloudy suspension is achieved.
- Doses greater than 4 ml should be divided equally into two syringes and injected into two separate sites.

4.3 Contraindications

VIDAZA is contraindicated in the following patients:

- Patients with known hypersensitivity to azacitidine or to any of the excipients of VIDAZA.
- Patients with malignant hepatic tumours.
- Patients must not receive live vaccines while being treated with VIDAZA.
- Pregnancy and breastfeeding (see section 4.6).
- VIDAZA is not recommended for use in children and adolescents below the age of 18.

4.4 Special warnings and precautions for use

Haematological toxicity:

Treatment with VIDAZA is associated with anaemia, neutropenia and thrombocytopenia, particularly during the first 2 cycles (see section 4.8). Complete blood counts should be performed as needed to monitor response and toxicity, but at least prior to each treatment cycle. After administration of the recommended dose for the first cycle, the dose for subsequent cycles should be reduced or delayed based on nadir counts and haematological response (see section 4.2). Patients should be advised to promptly report febrile episodes. Patients and healthcare professionals are also advised to be observant for signs and symptoms of bleeding.

Hepatic impairment:

No formal studies have been conducted in patients with hepatic impairment. Patients with extensive tumour burden due to metastatic disease have been reported to experience progressive hepatic coma and death during VIDAZA treatment, especially in such patients with baseline serum albumin < 30 g/L. VIDAZA is contraindicated in patients with malignant hepatic tumours (see section 4.3).

Renal impairment:

Renal abnormalities ranging from elevated serum creatinine to renal failure and death were reported in patients treated with intravenous (IV) VIDAZA in combination with other chemotherapeutic medicines for non-MDS conditions. In addition, renal tubular acidosis, (defined as a fall in serum bicarbonate to < 20 mmol/l in association with an alkaline urine and hypokalaemia (serum potassium < 3 mmol/l)) developed in subjects with CML treated with VIDAZA and etoposide. If unexplained reductions in serum bicarbonate (< 20 mmol/l) or

elevations of serum creatinine or BUN occur, the dosage should be reduced or administration delayed.

Patients should be advised to report oliguria and anuria to the healthcare professional immediately.

Patients with renal impairment should be closely monitored for toxicity since VIDAZA and/or its metabolites are primarily excreted by the kidney (see section 4.2).

Laboratory tests:

Liver function tests, serum creatinine and serum bicarbonate should be determined prior to initiation of therapy and prior to each treatment cycle. Complete blood counts should be performed prior to initiation of therapy and as needed to monitor response and toxicity, but at a minimum, prior to each treatment cycle, see also section 4.8 and 4.2.

Tumour Lysis Syndrome:

The patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.

Cardiac and pulmonary disease:

The safety and efficacy of azacitidine as contained in VIDAZA in patients with a history of severe congestive heart failure, clinically unstable cardiac disease or pulmonary disease have not been established. It is advised to exercise caution when prescribing VIDAZA to these patients. Cardiopulmonary assessment before and during the treatment should be considered.

Necrotising fasciitis:

VIDAZA therapy should be discontinued in patients who develop necrotising fasciitis and appropriate treatment should be promptly initiated.

Differentiation syndrome:

Cases of differentiation syndrome (also known as retinoic acid syndrome) have been reported in patients receiving injectable azacitidine as contained in VIDAZA. Differentiation syndrome may be fatal and symptoms and clinical findings include respiratory distress, pulmonary infiltrates, fever, rash, pulmonary oedema, peripheral oedema, rapid weight gain, pleural effusions, pericardial effusions, hypotension and renal dysfunction (see section 4.8). Treatment with high-dose IV corticosteroids and haemodynamic monitoring should be considered at first onset of symptoms or signs suggestive of differentiation syndrome. Temporary discontinuation of injectable azacitidine should be considered until resolution of symptoms and if resumed, caution is advised.

VIDAZA contains mannitol and may have a laxative effect.

4.5 Interaction with other medicines and other forms of Interaction

No formal clinical interaction studies with VIDAZA have been conducted.
Based on in vitro data, azacitidine metabolism does not appear to be mediated by cytochrome P450 isoenzymes (CYPs), UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), and glutathione transferases (GSTs); therefore, CYP inhibitors and inducers are unlikely to have any impact on the metabolism of azacitidine.

Clinically relevant inhibitory or inductive effects of azacitidine on the metabolism of cytochrome P450 substrates are unlikely (see section 5.2).

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/ Contraception in males and females

Women of childbearing potential should be advised to avoid pregnancy during treatment with VIDAZA and should use effective contraception during and up to 6 months after treatment. Men should be advised not to father a child while receiving treatment and must use effective contraception during and up to 3 months after treatment.

Pregnancy

VIDAZA may cause foetal harm when administered to a pregnant woman.

Azacitidine was teratogenic in animals. If this medicine is used during pregnancy or if a patient becomes pregnant while taking VIDAZA, the patient should be apprised of the potential hazard to the foetus.

Female partners of male patients receiving VIDAZA should not become pregnant.

Breastfeeding

Due to the potential serious adverse reactions in the nursing child, breastfeeding must be discontinued during VIDAZA therapy·

Fertility

There is no human data on the effect of azacitidine on fertility. Before starting treatment, male patients should be advised to seek counselling on sperm storage.

4.7 Effects on ability to drive and use machines

VIDAZA may have minor or moderate effects on mental and/or physical abilities to perform or execute tasks or activities requiring mental alertness, judgment and/or sound coordination and vision.

Patients who experience dizziness should not drive or use machines when taking VIDAZA.

4.8 Undesirable effects

Summary of the safety profile

Adult population with MDS, CMML and AML (20-30% marrow blasts)

Adverse reactions considered to be possibly or probably related to the administration of VIDAZA have occurred in 97 % of patients.

The most commonly reported adverse reactions with treatment with VIDAZA were haematological reactions (71,4 %) including anaemia, thrombocytopenia, neutropenia and leukopenia, gastrointestinal events (60,6 %) including nausea and vomiting, and injection site reactions (77,1 %).

Adverse reactions associated with intravenously administered VIDAZA were similar in frequency and severity compared with subcutaneously administered VIDAZA.

The most common serious adverse reactions (> 2 %) noted from the pivotal study (AZA PH GL 2003 CL 001) and also reported in the supporting studies (CALGB 9221 and CALGB 8921) included febrile neutropenia (8,0 %) and anaemia (2,3 %). Other less frequently reported serious adverse reactions (< 2 %) included neutropenic sepsis, pneumonia, thrombocytopenia and haemorrhagic events (e.g. cerebral haemorrhage).

Adult population aged 65 years or older with AML with > 30 % marrow blasts

The most commonly reported (≥ 30 %) adverse reactions with VIDAZA treatment were gastrointestinal events, including constipation (41,9 %), nausea (39,8 %), and diarrhoea (36,9 %), (usually Grade 1-2), general disorders and administration site conditions including pyrexia (37,7 %; usually Grade 1-2) and haematological events, including febrile neutropenia (32,2 %) and neutropenia (30,1 %), (usually Grade 3-4).

The most common serious adverse reactions (≥ 10 %) noted from AZA-AML-001 within the VIDAZA treatment arm included febrile neutropenia (25,0 %), pneumonia (20,3 %), and pyrexia (10,6 %). Other less frequently reported serious adverse reactions in the VIDAZA treatment arm included sepsis (5,1 %), anaemia (4,2 %), neutropenic sepsis (3,0 %), urinary tract infection (3,0 %), thrombocytopenia (2,5 %), neutropenia (2,1 %), cellulitis (2,1 %), dizziness (2,1 %) and dyspnoea (2,1 %).

The table below contains the adverse reactions for which a causal relationship with VIDAZA treatment could reasonably be established. Frequencies given are based on the observations during the clinical studies in MDS and AML and post marketing surveillance.

Frequencies are defined as: very common (≥ 1/10), common (≥ 1 /100 to < 1/10); and uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Tabulated list of adverse reactions

System Organ Class	Very common	Common	Uncommon	Rare	Not Known
Infections and infestations	pneumonia* (including bacterial, viral and fungal), nasopharyngitis	sepsis* (including bacterial, viral and fungal), neutropenic sepsis*, respiratory tract infection (includes upper and bronchitis), urinary tract infection, cellulitis, diverticulitis, oral fungal infection, sinusitis, pharyngitis, rhinitis, herpes simplex, skin infection			necrotising fasciitis*

System Organ Class	Very common	Common	Uncommon	Rare	Not Known
Neoplasms benign, malignant and unspecified (including cysts and polyps)					differentiation syndrome (see section 4.4)
Blood and lymphatic system disorders	febrile neutropenia*, neutropenia, leukopenia, thrombocytopenia, anaemia	pancytopenia*, bone marrow failure			
Immune system disorders			hypersensitivity reactions		
Metabolism and nutrition disorders	anorexia, decreased appetite, hypokalaemia	dehydration		tumour lysis syndrome	
Psychiatric disorders	insomnia	confusional state, anxiety			
Nervous system disorders	dizziness, headache	intracranial haemorrhage*, syncope, somnolence, lethargy			
Eye disorders		eye haemorrhage, conjunctival haemorrhage			

System Organ Class	Very common	Common	Uncommon	Rare	Not Known
Cardiac disorders		pericardial effusion	Pericarditis		
Vascular disorders		hypotension*, hypertension, orthostatic hypotension, haematoma			
Respiratory, thoracic and mediastinal disorders	dyspnoea, epistaxis	pleural effusion, exertional dyspnoea, pharyngolaryngeal pain		interstitial lung disease	
Gastrointestinal disorders	diarrhoea, vomiting, constipation, nausea, abdominal pain (includes upper and abdominal discomfort)	gastrointestinal haemorrhage* (includes mouth haemorrhage), haemorrhoidal haemorrhage, stomatitis, gingival bleeding, dyspepsia			
Hepatobiliary disorders			hepatic failure*, progressive hepatic coma		
Skin and subcutaneous tissue disorders	petechiae, pruritus (includes generalised), rash, ecchymosis	purpura, alopecia, urticaria, erythema, rash macular	acute febrile neutrophilic dermatosis, pyoderma gangrenosum		Cutaneous vasculitis

System Organ Class	Very common	Common	Uncommon	Rare	Not Known
Musculoskeletal, and connective tissue disorders	arthralgia, musculoskeletal pain (includes back, bone and pain in extremity)	muscle spasms, myalgia			
Renal and urinary disorders		renal failure*, haematuria, elevated serum creatinine	renal tubular acidosis		
General disorders and administration site conditions	pyrexia*, fatigue, asthenia, chest pain, injection site erythema, injection site pain, injection site reaction (unspecified)	bruising, haematoma, induration, rash, pruritus, inflammation, discoloration, nodule and haemorrhage (at injection site), malaise, chills, catheter site haemorrhage		injection site necrosis (at injection site)	
Investigations	weight decreased				

* = rarely fatal cases have been reported

Description of selected adverse reactions

Hypersensitivity:

Serious hypersensitivity reactions have been reported in patients receiving VIDAZA. In case of an anaphylactic-like reaction, treatment with VIDAZA should be immediately discontinued and appropriate symptomatic treatment initiated.

Haematologic adverse reactions:

The most commonly reported adverse reactions associated with VIDAZA treatment were haematological, including anaemia, thrombocytopenia, neutropenia and leukopenia. There is a greater risk of these events occurring during the first 2 cycles, after which they occur with less frequency in patients with restoration of haematological function. Most haematological adverse reactions were managed by routine monitoring of complete blood counts and delaying VIDAZA administration in the next cycle, prophylactic antibiotics and/or growth factor support (e.g. G-CSF) for neutropenia and transfusions for anaemia or thromobocytopenia as required.

Infections:

Myelosupression may lead to neutropenia and an increased risk of infection. Serious adverse reactions such as neutropenic sepsis (0,8 %) and pneumonia (2,5 %) were reported in patients receiving VIDAZA. Infections may be managed with the use of anti-infectives plus growth factor support (e.g. G-CSF) for neutropenia.

Bleeding:

Bleeding may occur with patients receiving VIDAZA. Serious adverse reactions such as gastrointestinal haemorrhage and intracranial haemorrhage have been reported. Patients should be monitored for signs and symptoms of bleeding, particularly those with pre-existing or treatment-related thrombocytopenia.

Skin and subcutaneous tissue adverse reactions:

The majority of skin and subcutaneous adverse reactions were associated with the injection site. The majority of adverse reactions occurred during the first 2 cycles and tended to

decrease with subsequent cycles. Subcutaneous adverse reactions such as injection site rash, inflammation, pruritus, erythema and skin lesion may require management with concomitant medicines, such as antihistamines, corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs).

Gastrointestinal adverse reactions:

The most commonly reported gastrointestinal adverse reactions associated with VIDAZA treatment included constipation, diarrhoea, nausea and vomiting. These adverse reactions were managed symptomatically with anti-emetics for nausea and vomiting; antidiarrhoeals for diarrhoea, and laxatives and/or stool softeners for constipation.

Renal adverse reactions:

Renal abnormalities, ranging from elevated serum creatinine to renal tubular acidosis, renal failure and death have been reported in patients treated with VIDAZA.

Hepatic adverse reactions:

Patients with extensive tumour burden due to metastatic disease have been reported to experience progressive hepatic coma and death during VIDAZA treatment.

Cardiac events:

Data from a clinical study allowing enrolment of patients with known history of cardiovascular or pulmonary disease showed an increase in cardiac events in patients with newly diagnosed AML treated with azacitidine (see section 4.4).

Elderly population:

There is limited safety information available with azacitidine in patients ≥ 85 years.

Post-marketing Data

The following events have been reported in the post-marketing setting:

- Interstitial lung disease.
- Tumour lysis syndrome.
- Injection site necrosis.
- Necrotising fasciitis.
- Acute febrile neutrophilic dermatosis.
- Pyoderma gangrenosum.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare providers are asked to report any suspected adverse reactions to SAHPRA via the "**6.04 Adverse Drug Reactions Reporting Form**", found online under SAHPRA's publications: https://www.sahpra.org.za/Publications/Index/8

4.9 Overdose

In the event of overdose, side effects will be exaggerated (see section 4.8). The patient should be monitored with appropriate blood counts and should receive supportive treatment, as necessary.

There is no known specific antidote for VIDAZA overdose.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agent, pyrimidine analogues; ATC code: L01BC07

Azacitidine is cytidine nucleoside analogue that incorporates into RNA and DNA. Azacitidine is believed to exert its antineoplastic effects by cytotoxicity to abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA. The cytotoxic effects of azacitidine may be due to inhibition of protein synthesis and activation of DNA damage pathways, due to incorporation into RNA and DNA, respectively. Incorporation of azacitidine into DNA also results in DNA hypomethylation and may allow the re-expression of genes involved in normal cell cycle regulation and differentiation. Non-proliferating cells are relatively insensitive to azacitidine.

5.2 Pharmacokinetic properties

The pharmacokinetics of azacitidine were studied following single 75 mg/m^2 doses given by subcutaneous and intravenous administration.

Absorption

Following subcutaneous administration of a single 75 mg/m^2 dose, azacitidine was rapidly absorbed after SC administration with peak plasma azacitidine concentrations of 750 + 403 ng/mL occurred at 0,25 h after dosing. The absolute bioavailability of azacitidine after subcutaneous relative to intravenous administration (single 75 mg/m^2 doses) was approximately 89 % based on area under the curve (AUC).

AUC and C_{max} of subcutaneous administration of azacitidine were approximately dose proportional within the 25 to 100 mg/m^2 dose range. Multiple dosing at the recommended dose-regimen does not result in accumulation of azacitidine.

Distribution

Following intravenous administration, the mean volume of distribution was 76 ± 26 l, and systemic clearance was 147 ± 47 l/h (mean apparent subcutaneous clearance was 167 ± 49 l/h).

Metabolism

Based on in vitro data, azacitidine metabolism does not appear to be mediated by cytochrome P450 isoenzymes (CYPs).

Azacitidine undergoes spontaneous hydrolysis and deamination mediated by cytidine deaminase.

In vitro studies of azacitidine with cultured human hepatocytes indicate that at concentrations of 1,0 µM to 100 µM (i.e. up to approximately 30-fold higher than clinically achievable concentrations), azacitidine does not induce cytochrome P450 isoenzymes (CYPs) 1A2, 2C19, or 3A4 or 3A5. In studies to assess inhibition of a series of P450 isoenzymes (CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4), azacitidine up to 100 µM did not produce inhibition. Therefore, CYP induction or inhibition by azacitidine at clinically achievable plasma concentrations is unlikely.

Excretion

Azacitidine is cleared from plasma with a mean elimination half-life ($t_{1/2}$) after subcutaneous administration of 41 ± 8 minutes. Published studies indicate that urinary excretion is the primary route of elimination of azacitidine and/or its metabolites. Following intravenous and subcutaneous administration of 14C azacitidine, 85 % and 50 % of the administered radioactivity was recovered in urine respectively, while < 1 % was recovered in faeces. The

mean elimination half-lives of total radioactivity (azacitidine and/or its metabolites) were similar after intravenous and subcutaneous administrations, i.e about 4 hours.

Pharmacokinetics in Children, the Elderly and Hepatic Impairment

No data are available.

Renal impairment

Severe renal impairment has no major effect on the PK exposure of azacitidine after single and multiple SC administrations. Therefore, azacitidine can be administered to patients with renal impairment without initial dose adjustment.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Mannitol (E421)

6.2 Incompatibilities

In the absence of compatibility studies, this medicine must not be mixed with other medicines.

6.3 Shelf life

Unopened powder vial:

48 months

After reconstitution:

- When reconstituted with refrigerated (2 °C and 8 °C) water for injections, the reconstituted suspension can be kept in the refrigerator (2 °C and 8 °C) for a maximum of 22 hours.

- After removal from refrigerated conditions, the suspension may be allowed to equilibrate to room temperature (25 ºC) for up to 30 minutes prior to administration.
- When stored at 25 ºC, the reconstituted product should be administered within 1 hour.
- From a microbiological point of view, the reconstituted product should be used immediately.

6.4 Special precautions for storage

Powder for injection:

Store at or below 25 °C.

After reconstitution:

For storage conditions after reconstitution of the medicine, see section 6.3.

6.5 Nature and contents of container

Colourless single use Type I glass vial sealed with a butyl rubber stopper and aluminium seal with plastic button.

6.6 Special precautions for disposal of a used medicine or waste materials derived from such medicine and other handling of the product

Cytotoxic medicine: Any unused product or waste material should be disposed of in accordance with local requirements.

7 THE HOLDER OF THE CERTIFICATE OF REGISTRATION

Key Oncologics (Pty) Ltd

39 – 11th avenue

Houghton Estate

Johannesburg, 2198

South Africa

8 REGISTRATION NUMBER(S)

A40/26/0521

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of registration: 5 March 2009

10 DATE OF REVISION OF TEXT

12 February 2024